What this domain asks
The governance and control system for attributable, legible, contemporaneous, original or verified-copy, accurate, complete, consistent, enduring, available records and their metadata throughout the lifecycle.
The domain should retain its own evidence, decision owner, materiality criteria, exception path, and consequence even when it shares organization identity, workflow, or technology with adjacent domains. Aggregation can support oversight; it should not erase the evidence behind different risks or operating outcomes.
Buyer questions
- Which record and metadata are authoritative?
- What can be created changed deleted reprocessed or overwritten?
- Who reviews which audit trails and when?
- Can records be reconstructed and rendered through retention?
- How are hybrid steps interfaces incidents and corrective actions governed?
Mapped workflows
Instrument Integration And Bidirectional Worklists
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for instrument integration and bidirectional worklists within this domain.
Raw Scientific-File Capture And SDMS Archive
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for raw scientific-file capture and SDMS archive within this domain.
Chromatography Acquisition Processing And Reporting
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for chromatography acquisition processing and reporting within this domain.
Electronic Signatures Audit Trails And Record History
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for electronic signatures audit trails and record history within this domain.
Role Identity Access And Segregation-Of-Duties Controls
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for role identity access and segregation-of-duties controls within this domain.
API Integration And Enterprise Interoperability
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for API integration and enterprise interoperability within this domain.
Deployment Administration Change Control And Validation Support
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for deployment administration change control and validation support within this domain.
Authority context
21 CFR Part 11
Part 11 sets criteria under which FDA considers electronic records and signatures trustworthy, reliable, and generally equivalent to paper records and handwritten signatures.
FDA Data Integrity Guidance
The guidance addresses complete, consistent, accurate data; metadata; audit trails; access; review; blank forms; testing into compliance; and investigation of data-integrity problems.
EU GMP Annex 11
Annex 11 addresses risk management, personnel, suppliers, validation, data, accuracy checks, storage, printouts, audit trails, change, security, incident management, signatures, business continuity, and archiving.
PIC/S PI 041-1
PI 041-1 describes data governance, risk, lifecycle, organizational controls, computerized and paper systems, audit trails, review, outsourcing, and remediation considerations.
Relevant operating models
- Enterprise LIMS And Laboratory-Informatics Suite
- Chromatography And Analytical Data System
- Scientific-Data Platform And SDMS
- Regulated Laboratory Execution And Manufacturing-Quality Platform
Evidence boundary
Lab Systems Index provides market, standards, regulatory, product, and operating research. It does not validate a computerized system, certify Part 11 or GxP compliance, accredit a laboratory, approve a method, determine scientific validity, interpret patient results, or replace laboratory, quality, validation, regulatory, security, legal, data-integrity, or scientific review. A provider's documented capability can identify a research candidate but cannot establish buyer-specific adequacy for this domain.